Skip to main content
. 2023 Jun 28;15(13):3386. doi: 10.3390/cancers15133386

Figure 2.

Figure 2

Efficacy results of the Bayesian network meta-analysis in the four first-line treatment groups for patients with HR+/HER2− ABC. (A) Forest plot of hazard ratios and 95% confidence intervals for overall survival in pairwise comparisons of the four first-line treatment groups; (B) forest plot of hazard ratios and 95% confidence intervals for progression-free survival in pairwise comparisons of the four first-line treatment groups; (C) hazard ratios, 95% confidence intervals, and ranking for overall survival (upper triangle in blue) and progression-free survival (lower triangle in yellow) of the network meta-analysis in the four first-line treatment groups. Palbo + NSAI, palbociclib plus letrozole/anastrozole; Ribo + NSAI, ribociclib plus letrozole/anastrozole; Abem + NSAI, abemaciclib plus letrozole/anastrozole; placebo + NSAI, placebo plus letrozole/anastrozole.